The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Xarelto



Bayer AGEU/1/08/472/025-033

Main Information

Trade NameXarelto
Active SubstancesRivaroxaban
Dosage FormFilm-coated tablet
Licence HolderBayer AG
Licence NumberEU/1/08/472/025-033

Group Information

ATC CodeB01AF Direct factor Xa inhibitors
B01AF01 rivaroxaban

Status

License statusAuthorised
Licence Issued22/05/2013
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Educational Materials - HCP

Educational Materials - Patient

« Back